UCB to File for China Approval of Parkinson's Disease Patch

UCB of Belgium reported positive results from two China Phase III trials of Neupro, a dopamine agonist patch product, for early and advanced-stage Parkinson's disease. The company said it would complete a CFDA filing this year for China approval of the Parkinson's treatment. Neupro, which was first approved in Europe in 2006, is currently sold in 46 countries. UCB focuses on itreatments for mmune system and CNS disorders. More details.... Stock Symbol: (Euronext: UCB) Share this with colleagues: // //